|1.||Fu, Yao: 1 article (01/2015)|
|2.||Gong, Tao: 1 article (01/2015)|
|3.||Luo, Jingwen: 1 article (01/2015)|
|4.||Cao, Xi: 1 article (01/2015)|
|5.||Sun, Xun: 1 article (01/2015)|
|6.||Zhang, Zhi-Rong: 1 article (01/2015)|
|7.||Chen, Li-Ming: 1 article (11/2009)|
|8.||Liang, Yong-Ju: 1 article (11/2009)|
|9.||Fu, Li-Wu: 1 article (11/2009)|
|10.||Tao, Li-Yang: 1 article (11/2009)|
01/05/2015 - "The biodistribution study was performed using a nude mice xenograft model, which demonstrates enhanced tumor uptake of DOX in the DOX/W198-LN treated group. "
11/01/2009 - "Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue."
|2.||Breast Neoplasms (Breast Cancer)
01/05/2015 - "Taken together, DOX/W198-LNs represent a promising formulation for overcoming MDR in breast cancer. "
01/05/2015 - "Coencapsulated DOX and W198 lipid nanoemulsions (DOX/W198-LNs) displayed significantly enhanced cytotoxicity in DOX-resistant human breast cancer cells (MCF-7/ADR) compared with DOX loaded lipid nanoemulsions (DOX-LNs) (p < 0.05), which is due to the enhanced intracellular uptake of DOX in MCF-7/ADR cells. "
01/05/2015 - "Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo."
01/05/2015 - "Our study aimed at developing a lipid nanoemulsion system for the coencapsulation of doxorubicin (DOX) and bromotetrandrine (W198) to reverse multidrug resistance (MDR) in breast cancer. "
|1.||Heterologous Transplantation (Xenotransplantation)